Drug intelligence / Profile preview

rabies immunoglobulin (human)

Development stage
Unknown
Lead developer
CSL Behring
Modality
Antibody-Based Therapeutics
Administration
Intramuscular, Intralesional
01

Overview

Berirab P is a human rabies immunoglobulin (HRIG) preparation used for passive immunization against rabies. It is administered as part of post-exposure prophylaxis (PEP) following potential exposure to the rabies virus, such as through animal bites. The product contains high titers of neutralizing antibodies (IgG) derived from the plasma of donors immunized with rabies vaccine. These antibodies provide immediate, short-term protection by neutralizing the virus at the site of entry before the patient's own immune system can produce antibodies in response to active vaccination. Berirab P is specifically a pasteurized formulation, ensuring viral safety through heat treatment. It is typically administered via infiltration around the wound site and intramuscular injection.

Brand names
Berirab PBerirabImogam Rabies-HTHyperRABKedRAB
Other names
rabies immunoglobulin (human)HRIGHuman Rabies Immunoglobulin

Beyond the preview

Go deeper on rabies immunoglobulin (human).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rabies immunoglobulin (human).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call